Kevin Kunzmann

An approval may be pending for the unique delivery system. An expert explains its benefit for nAMD patients and physicians alike.

A retina care team highlighted positive patient feedback from their makeshift system; could it be a long-term solution?

A greater rate of intravitreal injection appointments were delayed last year, causing worse patient scores in BCVA and OTC.

New cohort analyses show endophthalmitis was not significantly reduced in treatment encounters where both physicians and patients were masked.

Findings from YOSEMITE and RHINE show a significant rate of patients on faricimab were able to extend their dosing to once every 16 weeks after a year of therapy.

Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema.

A new cross-sectional analysis from ASRS 2021 show White patients are generally overrepresented in randomized, controlled trials for DME.

Josh Mali, MD, of The Eyes Associates, joins HCPLive to review the key news and developments coming out of the American Society of Retina Specialists 2021 Scientific Meeting.

A cohort assessment of the IRIS registry database shows about 1 in 10 patients to receive anti-VEGF and/or panretinal photocoagulation discontinue therapy for at least 1 year.

Montefiore experts discuss the emphasis on education at their MFM-Cardiology care program.

An obstetrician-gynecologist and a cardiologist discuss the inception of their joint cardiovascular care program for expecting mothers.

Michael Greenberg, MD, MPH, and Rick Nettles, MD, join Lungcast to discuss COVID-19 vaccine development, the 2021-22 flu season, RSV outbreaks, and more respiratory viruses.

Announced on September 24, the approval is for use as an adjunct to diet and other LDL-C-lowering therapies for reducing LDL-C in patients aged 10 years and older with heterozygous familial hypercholesterolemia.

The approval is based on 24- and 80-week findings showing significant benefit in LDL-C reduction with the subcutaneous injection drug.

Manesh Patel, MD, kicks off his first podcast by discussing HFpEF findings in EMPEROR-Preserved, the GUIDE-HF trial and more with his Duke colleague.

The regulatory setback is regarding a manufacturing facility concern not associated with the investigative drug, according to the company.

The TMIOA Medical Director and Principal Investigator discusses the idea behind hosting a mixed in-person and virtual conference for this year's Heart in Diabetes.

Matthew Budoff, MD, discusses what he views as hurdles to achieving optimal prescription of newer agents in the treatment of cardiometabolic conditions, including diabetes, heart failure, dyslipidemia, and more.

An expert considers the buildup of cardiovascular and cardiometabolic innovation, and the role of regulatory delays in it.

An overlooked aspect of an under-discussed condition, Andrea Dunaif, MD, provided an overview of the cardiovascular risk seen among women with polycystic ovary syndrome.

How inclisiran, bempedoic acid, and other investigative therapies may contribute to cardiometabolic disease management.

A discussion on the winning qualities of the CARDIA study, and why it's also hard to replicate.

The cardiologist discusses the lagging nature of US health care authorization and recommendation for already proven agents in cardiovascular risk reduction.

The Tulane Chief of Endocrinology recalls Dr. Frederick Banting's historic discovery in 1921, and how it still impacts diabetes care today.

Women with gestational diabetes face a twice greater risk of developing cardiovascular disease. Investigators are still seeking understanding of the association.

A look at how European experts have shaped risk assessment through demographic-centric algorithms.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

An expert weighs in on improving guidelines to reflect optimal real-world care for patients at high risk of cardiovascular events.

While drivers of gestational diabetes are not fully evidenced, data shows how it's linked to great likelihood of type 2 diabetes and cardiovascular events.

Though the trial observing dapagliflozin for severe COVID-19 did not achieve statistical significance, investigators believe it showed the agent's benefit in acute illness.